Coming Soon

Arecor is a biotechnology company focused on developing and commercializing advanced formulations of biologic drugs. The company utilizes its proprietary technology platform to enhance the stability and delivery of proteins and other macromolecules, aiming to improve patient outcomes and expand the therapeutic potential of existing treatments.
Public Funding Received
Developing Stable Liquid Chikungunya Vaccines to Improve Shelf-Life and Facilitate Worldwide Distribution
Feasibility Studies
2021-03-01
Transforming Diabetes Care
Collaborative R&D
2020-07-01
Expansion of superfast prandial insulin project
Feasibility Studies
2019-01-01
Development of a superfast acting prandial insulin
Collaborative R&D
2017-11-01
Validation of a novel preclinical development platform to enable high value therapeutic co-formulations
Collaborative R&D
2017-01-01
Newton Fund - DEVELOPMENT OF DIFFERENTIATED PRODUCT CONCEPTS FOR INSULIN GLARGINE
Collaborative R&D
2017-01-01
Liquid Glucagon: Improving Utilisation for Emergency Treatment of Severe Hypoglycemia
Collaborative R&D
2016-02-01
Vaccine Diluent Improvement for ECF-ITM
BIS-Funded Programmes
2015-12-01
Ultra-Long Acting Insulin Glargine
GRD Proof of Concept
2015-06-01
Improved downstream operation through formulation innovation
Collaborative R&D
2014-04-01
Novel screening approach for developing new stable biotherapeutic formulations
Collaborative R&D
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-07-01
Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness
GRD Proof of Concept
2013-01-01
Novel excipients to allow superior liquid antibody formulation at high concentration
Collaborative R&D